Proactive Investors
26 May 2026, 18:55 UTC · 3h ago
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
Source · https://www.proactiveinvestors.com/companies/news/1092908
Read source
Search tags
Proactive Investors
26 May 2026, 18:55 UTC · 3h ago
Source · https://www.proactiveinvestors.com/companies/news/1092908
Read sourceSearch tags
Story key points
4 claims · impact-rated
Bank of America cut its price objective for Hims & Hers Health (HIMS) from $28 to $25 and reiterated a Neutral rating. — A direct reduction in price target and a neutral rating from a major investment bank typically triggers immediate downward pressure on the stock.
-0.60HIMS faces a significant customer acquisition hurdle, requiring approximately 225,000 new oral Wegovy subscribers per quarter to meet the midpoint of its 2026 revenue guidance. — Achieving a 45% market share of new cash-pay patients is described as a 'high bar,' increasing the risk of a revenue miss.
-0.50A pricing increase from $39 in the first month to $149 in subsequent months is expected to drive elevated churn, creating a potential $85 million revenue headwind by Q4 2026. — High churn rates directly undermine the recurring revenue model and long-term sustainability of the GLP-1 product line.
-0.40HIMS' share of new observed telehealth customers rebounded to approximately 46% in April, up from 29-34% in the first quarter. — Recent data shows a recovery in market share capture, suggesting the company still has strong competitive appeal despite churn risks.
+0.30Impact vectors
8 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
Bank of America highlighted significant customer acquisition challenges, high churn risks, and lowered the price target.
Mentioned only as a benchmark for analyst estimates regarding the Wegovy patient pool.